Table 1.
Baseline and clinical characteristics of the 59 patients who were evaluated to validate the 20-item questionnaire
| Mean ± SD | |
|---|---|
| Number (male-to-female ratio) | 59 (22:37) |
| Age (years) | 66.85 ± 8.25 |
| Disease duration (years) | 6.14 ± 4.80 |
| Treatment duration (years) | 4.43 ± 4.00 |
| The daily dose of levodopa (mg/day) | 540.00 ± 296.21 |
| K-MMSE | 26.49 ± 2.85 |
| New questionnaire | 23.24 ± 22.29 |
| HY stage | 2.42 ± 0.58 |
| UPDRS | 45.78 ± 18.49 |
| Mentation | 3.26 ± 2.05 |
| ADL | 11.88 ± 6.22 |
| Motor | 27.91 ± 11.05 |
| Complications | 2.73 ± 2.97 |
| SEADL | 77.59 ± 15.89 |
| BDI | 22.38 ± 11.53 |
| PDQL | 115.53 ± 39.93 |
| Parkinson’s symptoms | 42.51 ± 14.14 |
| Systemic symptoms | 25.27 ± 9.64 |
| Social function | 19.21 ± 7.18 |
| Emotional function subscore | 28.54 ± 10.80 |
| ADQ | 19.21 ± 12.42 |
| FSS | 36.20 ± 15.69 |
K-MMSE Korean Mini-Mental Status Examination, HY Hoehn and Yahr, UPDRS Unified Parkinson’s Disease Rating Scale, ADL Activities of Daily Living, SEADL Schwab and England ADL, BDI Beck’s Depression Inventory, PDQL Parkinson’s Disease Quality of Life, ADQ Autonomic Dysfunction Questionnaire, FSS Fatigue Severity Scale